VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AFGCAmerican Financial Group, Inc.
$17.70$1.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAFGCFinancials

American Financial Group, Inc. (AFGC) Financials

22Y historyFree accessUpdated daily

AFGC's underwriting discipline remains a core strength, evidenced by a 81.4% combined ratio in 2025Q4, though revenue growth has decelerated to 3.7% as of 2026Q1.

AFGC Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03
Revenue8.03B8.12B8.01B7.45B6.81B6.23B5.58B8.08B6.99B6.8B6.45B6.28B5.65B5.02B4.72B4.75B4.5B294.1M344.1M364.7M414.99B342.42B266.65B
Revenue Growth %-0.9%1.34%7.49%9.43%9.36%11.62%-30.98%15.65%2.76%5.41%2.76%11.11%12.61%6.4%-0.72%5.63%1429.07%-14.53%-5.65%-99.91%21.19%28.42%-
Medical Costs & Claims1.06B4.39B00000-154M-161M-64M-46M134M-62M-74M404M363M378M463M549.9M463.8M477.65B519.9B447B
Medical Cost Ratio %13.21%54.06%0%0%0%0%0%-1.91%-2.3%-0.94%-0.71%2.13%-1.1%-1.47%8.57%7.64%8.41%157.43%159.81%127.17%115.1%151.83%167.64%
Gross Profit5.11B3.73B8.01B7.45B6.81B6.39B5.58B8.24B7.15B6.87B6.5B6.14B5.71B5.09B4.31B4.39B4.12B-168.9M-205.8M-99.1M-62.67B-177.49B-180.36B
Gross Margin %63.69%45.94%100%100%100%102.67%100%101.91%102.3%100.94%100.71%97.87%101.1%101.47%91.43%92.36%91.59%-57.43%-59.81%-27.17%-15.1%-51.83%-67.64%
Gross Profit Growth %--53.45%7.49%9.43%6.52%14.59%-32.27%15.2%4.15%5.65%5.74%7.56%12.2%18.09%-1.71%6.51%2538.72%17.93%-107.67%99.84%64.69%1.59%-
Operating Expenses601M2.66B41M36M36M41M47M878M825M776M690M627M4.95B4.26B4.1B3.83B3.43B-368.9M-618.9M-561M-303.64B-580.94B-528.82B
OpEx / Revenue %7.49%32.72%0.51%0.48%0.53%0.66%0.84%10.86%11.8%11.41%10.69%9.99%87.61%84.85%87.02%80.57%76.27%-125.43%-179.86%-153.83%-73.17%-169.66%-198.32%
Depreciation & Amortization00000187M0259M210M107M134M134M-730M-771M-474M00000000
Combined Ratio %20.7%86.78%0.51%0.48%0.53%0.66%0.84%8.96%9.5%10.47%9.98%12.12%86.52%83.38%95.59%88.21%84.68%32%-20.05%-26.65%41.93%-17.82%-30.68%
Operating Income4.51B1.07B7.97B7.42B6.77B1.1B5.53B812M728M955M968M884M730M771M474M560M689M200M413.1M461.9M240.97B403.45B348.46B
Operating Margin %56.21%13.22%99.49%99.52%99.47%17.73%99.16%10.05%10.42%14.04%15%14.08%12.92%15.36%10.05%11.79%15.32%68%120.05%126.65%58.07%117.82%130.68%
Operating Income Growth %--86.54%7.46%9.48%513.59%-80.04%581.28%11.54%-23.77%-1.34%9.5%21.1%-5.32%62.66%-15.36%-18.72%244.5%-51.59%-10.57%-99.81%-40.27%15.78%-
EBITDA2.55B1.15B7.97B7.42B6.77B1.29B5.53B1.07B938M1.06B1.1B1.02B000823M981M606.4M904.5M937.1M649.39M844.87M348.46B
EBITDA Margin %31.8%14.2%99.49%99.52%99.47%20.73%99.16%13.25%13.42%15.62%17.08%16.21%0%0%0%17.33%21.81%206.19%262.86%256.95%0.16%0.25%130.68%
Interest Expense84M80M76M76M85M94M88M68M62M85M77M74M73M71M85M85M78M70M71.3M72.5M73.23B71.89B57.32B
Non-Operating Income1.81B-80M7.97B7.42B6.77B-325M5.53B-154M-161M-64M-46M944M-18M4M-138M-83M-78M-185.9M185.6M37.2M240.53B402.78B-9.87B
Pretax Income1.12B1.07B1.12B1.07B1.12B1.33B339M1.11B639M724M787M565M626M689M537M560M689M315.9M638.9M697.6M356.81B589.54B301.01B
Pretax Margin %13.9%13.17%14.03%14.4%16.49%21.44%6.08%13.71%9.14%10.65%12.2%9%11.08%13.73%11.39%11.79%15.32%107.41%185.67%191.28%85.98%172.17%112.89%
Income Tax236M231M237M221M225M254M25M239M122M247M119M195M220M236M135M240M266M115.9M225.8M235.7M115.84B186.09B-47.45B
Effective Tax Rate %21.15%21.61%21.09%20.6%20.04%19.03%7.37%21.57%19.09%34.12%15.12%34.51%35.14%34.25%25.14%42.86%38.61%36.69%35.34%33.79%32.47%31.57%-15.77%
Net Income879M842M887M852M898M1.34B732M897M530M475M649M352M452M471M488M343M479M195.8M383.2M453.4M206.58B359.86B348.46B
Net Margin %10.95%10.37%11.07%11.43%13.19%21.5%13.12%11.1%7.58%6.98%10.06%5.61%8%9.39%10.35%7.22%10.65%66.58%111.36%124.32%49.78%105.09%130.68%
Net Income Growth %10.01%-5.07%4.11%-5.12%-32.93%82.92%-18.39%69.25%11.58%-26.81%84.38%-22.12%-4.03%-3.48%42.27%-28.39%144.64%-48.9%-15.48%-99.78%-42.59%3.27%-
EPS (Diluted)10.5510.0810.5710.0510.5312.628.219.865.855.297.333.944.975.165.093.334.331.683.113.762675.494859.824827.55
EPS Growth %10.71%-4.64%5.17%-4.56%-16.56%53.72%-16.73%68.55%10.59%-27.83%86.04%-20.72%-3.68%1.38%52.85%-23.09%157.74%-45.98%-17.29%-99.86%-44.95%0.67%-
EPS (Basic)-10.0810.5710.0610.5512.708.259.985.965.417.474.024.975.165.093.394.391.713.263.842720.274906.904879.61
Diluted Shares Outstanding83.3M83.5M83.9M84.8M85.3M85.6M89.2M91M90.6M89.8M88.5M89.4M91M91.2M95.9M102.9M110.5M116.7M123.2M120.5M77.21M74.05M72.18M

Key Metrics

Growth RegimeMixed
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Underwriting volatility and litigation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Exhibits Cyclical Softening

As reported in recent financial filings, AFGC's revenue growth has fluctuated significantly, moving from a 10.6% expansion in 2024Q3 to a 3.7% increase by 2026Q1, suggesting that the company is navigating a challenging pricing environment within its core specialty insurance niches.

The deceleration in top-line growth appears to reflect a transition in the commercial insurance cycle where competitive pressures may be limiting rate increases. Investors should monitor whether this trend indicates a strategic withdrawal from certain lines to preserve underwriting discipline or a broader loss of market share in key specialty segments.

Underwriting Discipline Drives Profitability Resilience

Based on the provided data, AFGC maintained a combined ratio of 81.4% in 2025Q4, which underscores a robust underwriting performance that significantly outperforms the industry benchmark of 100% and suggests that the company's decentralized niche model remains highly effective at managing loss costs.

The ability to sustain such low combined ratios implies that the company is successfully pricing risk in its specialized portfolios despite potential inflationary pressures. This margin profile suggests that AFGC is not currently reliant on investment income to achieve overall profitability, providing a substantial buffer against market volatility.

Reserve Volatility Masks Underlying Trends

According to historical income statement data, the company reported erratic loss figures, including negative loss ratios in early 2024, which suggests that significant prior-year reserve releases may be artificially inflating current-period earnings and warranting deeper scrutiny of the underlying accident-year loss development.

The extreme variance in reported claims, ranging from negative values to $1.1 billion in 2025Q4, indicates that accounting adjustments for prior-year reserves are a primary driver of quarterly net income fluctuations. Analysts should investigate whether these releases are sustainable or if they are masking a potential deterioration in current-year underwriting profitability.

Capital Efficiency Remains Underutilized

As indicated by the company's financial structure, AFGC maintains an exceptionally low debt-to-equity ratio of 0.38, which suggests a fortress balance sheet that provides significant solvency protection but may simultaneously indicate an inefficient capital structure that limits potential return on equity for shareholders.

While this conservative leverage profile protects the firm against systemic shocks, it may suggest that management is failing to optimize its cost of capital in a high-interest-rate environment. Investors should monitor whether this excess liquidity will be deployed through further special dividends or if it remains a drag on long-term ROE.

AFGC — Frequently Asked Questions

Quick answers to the most common questions about buying AFGC stock.

What was American Financial Group, Inc.'s (AFGC) revenue in 2025?

For fiscal year 2025, American Financial Group, Inc. (AFGC) reported total revenue of $8.12B. This represents a 97.0% decline compared to $266.65B in 2003.

Is American Financial Group, Inc. (AFGC) profitable?

American Financial Group, Inc. (AFGC) is profitable, generating $842.0M in net income for the fiscal year ending 2025 with a net profit margin of 10.4%.

What is American Financial Group, Inc.'s operating profit margin?

American Financial Group, Inc. (AFGC) reported an operating income of $1.07B, resulting in an operating profit margin of 13.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is American Financial Group, Inc.'s gross profit and gross margin?

American Financial Group, Inc. (AFGC) generated $3.73B in gross profit for the year, representing a gross profit margin of 45.9%. This demonstrates the company's core pricing power and production efficiency.